Evidence map›Paper›PMID 36967405›Full record

ArticleCancer chemotherapy and pharmacology2023

Correction to: A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C.

Richard Kim, Alexis D Leal, Aparna Parikh, David P Ryan, Shining Wang, Brittany Bahamon, Neeraj Gupta, Aaron Moss, Joanna Pye, Harry Miao and 2 more

Open access · hybridAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer chemotherapy and pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Richard KimDepartment of Gastroenterology Oncology, Moffitt Cancer Center, Vincent A. Stabile Research Building, 12902 USF Magnolia Drive, Tampa, FL, 33612, USA. richard.kim@moffitt.org.ORCID http://orcid.org/0000-0002-8448-844X
Alexis D LealDivision of Medical Oncology, University of Colorado School of Medicine, Aurora, CO, USA.
Aparna ParikhDivision of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
David P RyanDivision of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Shining WangOncology Clinical Science, Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.
Brittany BahamonTranslational Medicine, Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.
Neeraj GuptaQuantitative Clinical Pharmacology, Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.
Aaron MossPharmacology/Toxicology, Audentes Therapeutics, Inc., San Francisco, CA, USA.
Joanna PyeOncology Statistics, Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.
Harry MiaoClinical Development, Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.
Haig InguilizianGlobal Patient Safety and Evaluation, Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.
James M ClearyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Takeda (United States) · USHarvard University · USMoffitt Cancer Center · USUniversity of Colorado Denver · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID36967405
PMCPMC10068635
OpenAlexW4360976751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.